Home Cart Sign in  
Chemical Structure| 936890-98-1 Chemical Structure| 936890-98-1

Structure of OSI-027
CAS No.: 936890-98-1

Chemical Structure| 936890-98-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

OSI-027 (ASP7486) is a potent, selective, orally active, and ATP-competitive mTOR kinase inhibitor with an IC50 of 4 nM. It targets both mTORC1 and mTORC2 with IC50s of 22 nM and 65 nM, respectively.

Synonyms: ASP7486; CERC 006; AEVI-006

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of OSI-027

CAS No. :936890-98-1
Formula : C21H22N6O3
M.W : 406.44
SMILES Code : O=C([C@H]1CC[C@H](C2=NC(C(N3)=CC4=C3C(OC)=CC=C4)=C5C(N)=NC=NN52)CC1)O
Synonyms :
ASP7486; CERC 006; AEVI-006
MDL No. :MFCD20275101
InChI Key :JROFGZPOBKIAEW-UHFFFAOYSA-N
Pubchem ID :135398516

Safety of OSI-027

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of OSI-027

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • mTORC1

    mTORC1, IC50:22 nM

  • mTORC2

    mTORC2, IC50:65 nM

  • mTOR

    mTOR, IC50:4 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HeLa cells 1 μM To evaluate the effect of OSI-027 on mTOR signaling, results showed that OSI-027 inhibited both mTORC1 and mTORC2 activity. PMC3077087
A549 cells 100 nM 48 hours OSI-027 combined with trametinib yielded a potent synergistic effect on the proliferation of NSCLC cells, inhibiting cell growth and inducing cell death. PMC8375233
H1650 cells 100 nM 48 hours OSI-027 combined with trametinib yielded a potent synergistic effect on the proliferation of NSCLC cells, inhibiting cell growth and inducing cell death. PMC8375233
HNSCC cell lines (UMSCC1, Cal 33, 686LN, FaDu, PCI-15B) 0.3 nM to 10 μM 3 days OSI-027 inhibited proliferation of HNSCC cell lines in a dose-dependent manner and significantly reduced phosphorylation of downstream targets such as p-AKT, p-4E-BP1, p-p70s6K, and p-PRAS40. PMC3514742
UMSCC1 and Cal 33 cells 0.3, 0.5, 0.75, 1.0, 1.25 μM 24 hours OSI-027 inhibited phosphorylation of downstream TORC1 and TORC2 targets in a dose-dependent manner, indicating its suppression of the mTOR signaling pathway. PMC3514742
HaCaT cells 1 μmol/L 6 hours OSI-027 inhibited both basal and glucocorticoid-induced REDD1 expression PMC6634309
CEM cells 1 μmol/L 6 hours OSI-027 inhibited both basal and glucocorticoid-induced REDD1 expression PMC6634309
RD cells 10 μM 24 hours Induced macropinocytosis, leading to cell death PMC6900636
RH30 cells 10 μM 24 hours Induced macropinocytosis, leading to cell death PMC6900636
HeLa cells 50 μM 24 hours Induced cytoplasmic vacuolization PMC6900636
MCF7 cells 50 μM 24 hours Induced cytoplasmic vacuolization PMC6900636
A549 cells 50 μM 24 hours Induced cytoplasmic vacuolization PMC6900636
HCC cells 0.3125, 0.625, 1.25, 2.5, 5.0, 10, 20 µmol/L 48 hours OSI-027 significantly inhibited HCC cell proliferation in a dose-dependent manner PMC4866512
HL-7702 cells 0.25, 0.50, 1.0, 2.0, 4.0, 8.0, 16 µmol/L 48 hours OSI-027 had a lower cytotoxicity in HL-7702 cells PMC4866512
ASZ001 cells 5 μM, 10 μM, 25 μM, 100 μM 24 hours To assess the effect of OSI-027 on the Hh signaling pathway, results showed that OSI-027 treatment did not significantly alter Gli1 mRNA expression. PMC9924159
ASZ001 cells 5 μM, 10 μM, 25 μM, 100 μM 4 days To assess the effect of OSI-027 on BCC cell growth, results showed that OSI-027 treatment significantly inhibited tumor cell growth after 4 days. PMC9924159
RD cells 5 μM 24 hours Combined treatment with RVX-208 and OSI-027 was more effective in reducing the expression of p-AKT/AKT, p-mTOR/mTOR, p-p70S6K/p70S6K, p-4EBP1/4EBP1, and the cell cycle protein cyclin D1 compared to the vehicle control or individual drug administration PMC9262843

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice GEO colorectal xenograft model Oral 2 mg/kg body weight Single injection, 5, 9, and 24 hours before initiation To evaluate the effect of OSI-027 on tumor growth, results showed that OSI-027 significantly inhibited tumor growth. PMC3077087
Nude mice HNSCC xenograft model OSI-027: Oral gavage; Cetuximab: Intraperitoneal injection 10 mg/kg once daily for 21 days Combined treatment with OSI-027 and cetuximab significantly reduced tumor volumes, demonstrating enhanced antitumor efficacy compared to either treatment alone. PMC3514742
Nude mice RMS xenograft model Oral 65 mg/kg Once daily for 12 days Reduced RMS tumor growth, induced macropinocytosis PMC6900636
nude mice HCC xenograft model oral and caudal vein injection OSI-027: 50 mg/kg; Cetuximab: 0.02 mg OSI-027: Daily; Cetuximab: Twice weekly for 14 days The combination of OSI-027 and doxorubicin significantly enhanced tumor growth inhibition PMC4866512
Nude mice Human rhabdomyosarcoma xenograft model Oral 30 mg/kg 1, 2, and 4 hours Combination treatment with RVX-208 and OSI-027 significantly reduced tumor growth in eRMS xenograft mice compared to single-agent treatment with RVX-208 or OSI-027 PMC9262843

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00698243 Any Solid Tumor or Lymphoma PHASE1 COMPLETED 2025-02-13 Karmanos Cancer Institute, Det... More >>roit, Michigan, 48201, United States|University Hospitals Leuven, Leuven, 3000, Belgium|Royal Mardsen Hospital, Sutton, Surrey, SM2 5PT, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.46mL

0.49mL

0.25mL

12.30mL

2.46mL

1.23mL

24.60mL

4.92mL

2.46mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories